Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Artivion Inc(AORT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AORT
11/06/2026: AORT (1-star) is a SELL. SELL for 1 day. Simulated Profits (-20.21%). Updated daily EoD!
Artivion Inc is a specialized medical device company focused on the cardiac and vascular surgical markets, known for its proprietary BioGlue sealant and advanced mechanical heart valves. The company has successfully pivoted from a tissue-processing base to an innovation-led strategy that builds deep relationships with cardiovascular surgeons. Its main opportunity lies in the continued adoption of its hybrid aortic repair products in global markets. Risks include significant competition from large-cap med-tech incumbents and the potential for shifts toward less invasive surgical technologies. The stock is best suited for growth-oriented investors who are willing to navigate the volatility typical of niche, smaller-cap medical device companies.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers a compelling growth story based on the rollout of specialized medical devices in the high-acuity surgical segment. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive price trends and sustained revenue beat signals. |
| Value investor | Weak fit | Valuation is often tied to future growth potential rather than traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | Small-cap med-tech carries higher volatility and execution risk compared to large-cap alternatives. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Small-cap health stocks can experience significant swings based on clinical or regulatory news. |
| Valuation risk | Medium | Market expectations for growth are high and must be met to sustain current price levels. |
| Competition risk (Structural Heart) | High | Large competitors have deeper resources for R&D and aggressive market defense. |
| Business quality | Medium | Artivion has a strong niche position but is smaller and less diversified than major peers. |
| Dividend income | Low / none | Investors looking for steady income streams will not find them here. |
| Execution risk | Medium / high | Success depends on constant product innovation and effective clinical adoption. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 38.66% | Avg. Invested days 51 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 985.36M USD | Price to earnings Ratio - | 1Y Target Price 40.91 |
Price to earnings Ratio - | 1Y Target Price 40.91 | ||
Volume (30-day avg) 630.3K shares | Beta 1.28 | 52 Weeks Range 19.16 - 48.25 | Updated Date 11/07/2026 |
52 Weeks Range 19.16 - 48.25 | Updated Date 11/07/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Aortic Medical Devices | Stents, grafts, and surgical sealants like BioGlue used in complex aortic procedures. | This is the primary growth engine and high-margin component of the business. |
| Mechanical Heart Valves | On-X mechanical valves and associated surgical instrumentation. | Provides a specialized, technology-driven revenue stream for cardiac procedures. |
| Geography | Direct and distributor-led sales across North America, Europe, and Asia-Pacific. | Diversification outside the US is a key ongoing initiative for broader growth. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When After Market | Estimate 0.11 | Actual 0.08 |
Profitability
Profit Margin -3.65% | Operating Margin (TTM) 6.82% |
Management Effectiveness
Return on Assets (TTM) 1.93% | Return on Equity (TTM) -3.98% |
Valuation
Trailing PE - | Forward PE 38.02 | Enterprise Value 1.34B | Price to Sales(TTM) 2.04 |
Enterprise Value 1.34B | Price to Sales(TTM) 2.04 | ||
Enterprise Value to Revenue 3.32 | Enterprise Value to EBITDA 30.66 | Shares Outstanding 48.76M | Shares Floating 46.36M |
Shares Outstanding 48.76M | Shares Floating 46.36M | ||
Percent Insiders 4.29 | Percent Institutions 97.62 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.